

score of 0 or 1(IGA Clear) at week 24 against 22% of patients in the placebo group ($p < 0.05$).

The most common adverse events (AE's) reported were lymphocytopenia, eosinophilia and gastrointestinal (GI) disorders, such as diarrhoea, nausea, abdominal pain and vomiting.

"Given the positive clinical data in this study, PPC-06 may have a potential to serve as an important therapeutic option for psoriasis patients in a market with limited oral treatments. We thank all the patients, investigators and study staff whose ongoing participation helped us achieve this target," said Sagar Munjal, MD, MS, Chief Medical Officer Promius Pharma/VP Clinical Development & Medical Affairs.